CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.480

-0.7%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (598)	7/12/2006 12:27:27 PM
From: Jim Oravetz	Read Replies (1) of 668

Curis: Enrollment For Basal Cell Carcinoma Phase I Halted DOW JONES NEWSWIRES July 11, 2006 5:18 p.m. Curis Inc. (CRIS) and Genentech Inc. (DNA) halted enrollment in the basal cell carcinoma Phase I trial and won't move ahead with the Phase I molecule as currently formulated. Curis, a Cambridge, Mass., drug development company, said the first two segments of the Phase I enrollment didn't reveal any safety concerns. But the third segment showed the formulation didn't downregulate the targeted pharmacodynamic marker in this tumor, suggesting the drug candidate may not be adequately penetrating human skin. The decision to halt enrollment in the Phase I trial doesn't affect the systemic Hedgehog antagonist collaboration with Genentech for the treatment of systemic solid tumor cancers. In June 2003, Curis began collaborating with Genentech to develop Hedgehog pathway inhibitors. In after-hours trading, Genentech's shares fell to $82.45 from its close of $84.06 in New York Stock Exchange composite trading.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next